The market size of the Global Radioligand Therapy Market in the year 2019 is valued at 7.31 billion and is predicted to reach 12.53 billion by the year 2030 at an 6.4% CAGR during the forecast period.
Curious about this latest version of report? Obtain Report Details@ https://www.insightaceanalytic.com/report/global-radioligand-therapy-market/1281
Radioligand therapy (RLT) is a cancer treatment strategy that uses targeted medicines. A radiopharmaceutical is injected or infused into a vein in the arm or leg. RLT (radioligand therapy) is a systemic therapy used to treat metastasized disease. Radiopharmaceuticals bind to a cancer target in radioligand therapy. Increased pharmaceutical manufacturer footprint in key areas is expected to fuel the global radioligand therapy market. The global radioligand therapy treatment market is likely to be driven by research and development of radioligand therapy candidates to treat a wide range of cancer types. Lu-PSMA-617, a radioligand therapy candidate developed by Endocytic, is now undergoing a phase III clinical trial for the treatment of prostate cancer. Industry leaders in the radioligand therapy industry are making strategic acquisitions to help manufacturers increase their cancer product pipeline. Thus, the market is likely to be driven during the forecast period by the approval and commercialization of pipeline drugs soon. Also, expanding radiopharmaceutical coverage and the role of radioligand in drug discovery are further fueling the market’s growth over the upcoming years. Besides, the market is expected to be hampered by high treatment costs and complex reimbursement processes, as well as increased competition from generics. Additionally, Companies’ propensity for product launches and approval suggests that they are continuing to bring new products to the market for radioligand therapy, which is primarily attributed to rising cancer prevalence, rising clinical research activity, and rising key players’ initiatives driving the market over the upcoming years. Rapid increases in per-capita healthcare spending, as well as rising public demand for low-cost healthcare, are propelling the expansion of healthcare products (particularly cancer devices) in these countries.
List of Prominent Players in the Radioligand Therapy Market:
Johnson & Johnson Services, Inc.
Pfizer Inc.
Anneal Pharmaceuticals LLC
Novartis International AG
POINT Biopharma Global Inc
Fusion Pharma
Clovis Oncology
Telex Pharmaceuticals
Lathes Holdings, Inc. (Progenies Pharmaceuticals)
Bayer AG
Molecular Partners
ITM Isotope Technologies Munich SE
Curium Pharma
Precure
Radio Medix
Other Prominent Players
For More Information @ https://www.insightaceanalytic.com/report/global-radioligand-therapy-market/1281
Market Dynamics:
Drivers-
An increased pharmaceutical manufacturer footprint will likely boost the market in key areas. Research and development of radioligand therapy candidates to treat a wide range of cancer types is projected to drive the worldwide radioligand therapy treatment market. Rapid increases in per-capita healthcare spending, as well as rising public demand for low-cost healthcare, are propelling the expansion of healthcare products (particularly cancer devices) in these countries. In addition, the increasing demand for Radioligand Therapy materials owing to their qualities such as simple disposal and inexpensive manufacturing costs is anticipated to contribute to the expansion of the worldwide Radioligand Therapy market.
Challenges:
Besides, the market is expected to be hampered by high treatment costs and complex reimbursement processes, as well as increased competition from generics. It is anticipated that a lack of knowledge in emerging nations would impede the growth of the Radioligand Therapy industry. However, the high cost of Radioligand Therapy and are factor expected to hamper the overall development of the Radioligand Therapy market over the coming years.
Regional Trends:
The Radioligand Therapy market in North America is anticipated to dominate the market in terms of revenue and expand at a rapid CAGR in the near future. Because of the high rate of adoption of radioligand treatment products following FDA approval, North America is the main market for radioligand therapy (RLT). Additionally, growth in research facilities, an increase in cancer prevalence, and increased government funding are expected to boost the market in the region during the forecast period. Several firms are seeking to maintain their market position by launching new goods and soliciting money for the development of new products for radioligand therapy innovation from various sample kinds. Product launches, product approvals, business finance, and synergistic actions were all seen by key market players in the worldwide radioligand treatment market.
Recent Developments:
- In March 2022, Novartis announced that the US Food and Drug Administration (FDA) approved PluvictoTM (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adults with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread (metastatic)1. These individuals have had various cancer therapies (androgen receptor pathway inhibition and taxane-based chemotherapy).
- In Sept 2021, Telix Pharmaceuticals Limited has partnered with Kettering Health, a faith-based network of 13 hospitals, ERs, and outpatient clinics. The parties have signed a Memorandum of Understanding (MOU) formalizing their intent to work together to foster late-stage clinical research into Telix’s investigational PSMA1-targeting radiopharmaceuticals, illuccix® (Kit for the preparation of 68Ga-PSMA-11 injection, for PET diagnostic imaging) and Lu-177 PSMA (TLX591, for radioligand therapy), and to establish Kettering Health as a regional centre of excellence for PET Molecular Imaging (Ml) and Theranostics.
Segmentation of Radioligand Therapy Market-
By Biomarker:
- Prostate-Specific Membrane Antigen
- Ki 67 Expression and Grading
- Cytochrome P450 17A1 Inhibitor
By Indications
- Prostate Cancer
- Neuroendocrine Tumor (NETs)
- Other Indications
By Products
- Approved Products
- Potential Pipeline”
By Region-
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Request for ToC/Proposal: https://www.insightaceanalytic.com/request-sample/1281
Contact Information:
+1 551 226 6109 Email: info@insightaceanalytic.com
